Attovia Therapeutics (NASDAQ:ATTO) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Attovia Therapeutics (NASDAQ:ATTO) to a sell rating in a research note published on Saturday morning,Wall Street Zen reports.

Several other equities analysts have also recently commented on ATTO. Morgan Stanley began coverage on shares of Attovia Therapeutics in a research report on Monday, August 31st. They issued an “overweight” rating and a $39.00 price target for the company. Leerink Partners started coverage on Attovia Therapeutics in a research note on Monday, August 31st. They issued an “outperform” rating and a $52.00 price objective on the stock. Zacks Research upgraded Attovia Therapeutics to a “hold” rating in a report on Friday, September 4th. Royal Bank Of Canada initiated coverage on Attovia Therapeutics in a research note on Monday, August 31st. They set an “outperform” rating and a $45.00 target price for the company. Finally, Citigroup started coverage on Attovia Therapeutics in a report on Monday, August 31st. They set a “buy” rating and a $30.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.20.

Attovia Therapeutics Stock Performance

NASDAQ ATTO opened at $22.14 on Friday. Attovia Therapeutics has a 1-year low of $16.15 and a 1-year high of $28.00.

Attovia Therapeutics (NASDAQ:ATTO) last issued its quarterly earnings results on Wednesday, September 2nd. The company reported ($4.88) earnings per share (EPS) for the quarter. The firm had revenue of $0.45 million for the quarter. Sell-side analysts anticipate that Attovia Therapeutics will post -4.06 EPS for the current fiscal year.

Insider Buying and Selling at Attovia Therapeutics

In other Attovia Therapeutics news, major shareholder Redmile Group, Llc acquired 400,000 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were acquired at an average price of $17.00 per share, for a total transaction of $6,800,000.00. Following the acquisition, the insider owned 1,182,854 shares in the company, valued at $20,108,518. The trade was a 51.10% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Colin Walsh bought 500,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were acquired at an average price of $17.00 per share, with a total value of $8,500,000.00. Following the purchase, the director owned 3,020,632 shares of the company’s stock, valued at $51,350,744. The trade was a 19.84% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders acquired 2,740,587 shares of company stock worth $47,269,979. Corporate insiders own 0.99% of the company’s stock.

About Attovia Therapeutics

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biotechnology company focused on developing antibody-based medicines for immune-mediated and inflammatory diseases. Its research programs are designed to address conditions in which dysregulated immune signaling contributes to disease.

The company’s activities include discovering, developing and advancing biologic drug candidates through preclinical and clinical testing. Attovia’s pipeline is centered on targeted therapies intended to modulate key pathways involved in inflammation and immune responses, with the goal of treating patients with significant unmet medical needs.

Attovia Therapeutics is headquartered in the United States and operates as a development-stage biopharmaceutical company.